Spherical nucleic acids as an infectious disease vaccine platform

Michelle H. Teplensky,Max E. Distler,Caroline D. Kusmierz,Michael Evangelopoulos,Haley Gula,Derek Elli,Anastasia Tomatsidou,Vlad Nicolaescu,Ian Gelarden,Anjana Yeldandi,Daniel Batlle,Dominique Missiakas,Chad A. Mirkin
DOI: https://doi.org/10.1073/pnas.2119093119
IF: 11.1
2022-03-21
Proceedings of the National Academy of Sciences
Abstract:Significance Using SARS-CoV-2 as a relevant case study for infectious disease, we investigate the structure–function relationships that dictate antiviral spherical nucleic acid (SNA) vaccine efficacy. We show that the SNA architecture can be rapidly employed to target COVID-19 through incorporation of the receptor-binding domain, and that the resulting vaccine potently activates human cells in vitro and mice in vivo. Furthermore, when challenged with a lethal viral infection, only mice treated with the SNA vaccine survived. Taken together, this work underscores the importance of rational vaccine design for infectious disease to yield vaccines that elicit more potent immune responses to effectively fight disease.
multidisciplinary sciences
What problem does this paper attempt to address?